Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2014', provides an overview of the Proliferative Diabetic Retinopathy (PDR)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Proliferative Diabetic Retinopathy (PDR), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Proliferative Diabetic Retinopathy (PDR) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Proliferative Diabetic Retinopathy (PDR) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Proliferative Diabetic Retinopathy (PDR) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Proliferative Diabetic Retinopathy (PDR) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Proliferative Diabetic Retinopathy (PDR) Overview 6
Therapeutics Development 7
Pipeline Products for Proliferative Diabetic Retinopathy (PDR) - Overview 7
Pipeline Products for Proliferative Diabetic Retinopathy (PDR) - Comparative Analysis 8
Proliferative Diabetic Retinopathy (PDR) - Therapeutics under Development by Companies 9
Proliferative Diabetic Retinopathy (PDR) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Proliferative Diabetic Retinopathy (PDR) - Products under Development by Companies 12
Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development 13
OcuCure Therapeutics, Inc. 13
Sirnaomics, Inc. 14
Ohr Pharmaceutical Inc. 15
Icon Bioscience, Inc. 16
Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
squalamine lactate - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
OC-10X - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
STP-601 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Lycium Anti-Angiogenic Proteoglycan - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drug for Proliferative Diabetic Retinopathy - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Proliferative Diabetic Retinopathy (PDR) - Recent Pipeline Updates 33
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H2 2014 7
Number of Products under Development for Proliferative Diabetic Retinopathy (PDR) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Proliferative Diabetic Retinopathy (PDR) - Pipeline by OcuCure Therapeutics, Inc., H2 2014 13
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Sirnaomics, Inc., H2 2014 14
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ohr Pharmaceutical Inc., H2 2014 15
Proliferative Diabetic Retinopathy (PDR) - Pipeline by Icon Bioscience, Inc., H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Proliferative Diabetic Retinopathy (PDR) Therapeutics - Recent Pipeline Updates, H2 2014 33
Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H2 2014 36